Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tao Li, Xin Li, Hui Chen, Kai-Zhao Huang, Qi Xie, Han-Yu Ge, Shen-Meng Gao, Jian-Hua Feng, Jun-Jun Yang, Zhan-Guo Chen & Xiao-Qun Zheng. (2021) Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor for Patients with Chronic Myeloid Leukemia. Cancer Management and Research 13, pages 1233-1243.
Read now
Read now
Shady Adnan-Awad, Matti Kankainen & Satu Mustjoki. (2021) Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leukemia & Lymphoma 62:9, pages 2064-2078.
Read now
Read now
Elias J. Jabbour, Martin F. Mendiola, Melissa Lingohr-Smith, Jay Lin & Dinara Makenbaeva. (2019) Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. Journal of Medical Economics 22:11, pages 1113-1118.
Read now
Read now
Elias J. Jabbour, Lisa R. Siegartel, Jay Lin, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2019) Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leukemia & Lymphoma 60:3, pages 668-674.
Read now
Read now
Elias J. Jabbour, Lisa R. Siegartel, Jay Lin, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2018) Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. Journal of Medical Economics 21:10, pages 1036-1040.
Read now
Read now
Elias J. Jabbour, Jay Lin, Lisa R. Siegartel, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2017) Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. Journal of Medical Economics 20:9, pages 1007-1012.
Read now
Read now
Articles from other publishers (26)
Hend Attia, Dina Adel Fouad & Heba Samy. (2023) The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome. Egyptian Journal of Medical Human Genetics 24:1.
Crossref
Crossref
Jayastu Senapati, Elias Jabbour, Hagop Kantarjian & Nicholas J. Short. (2022) Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37:1, pages 5-17.
Crossref
Crossref
Jialu Ma, Nathan Pettit, John Talburt, Shanzhi Wang, Sherman M. Weissman & Mary Qu Yang. (2022) Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia. International Journal of Molecular Sciences 23:22, pages 14335.
Crossref
Crossref
Ismail Siti Mariam, Ramli Norhidayah, Abu Bakar Zulaikha, Mohd Yunus Nazihah, Hassan Rosline, Ghazali Anis Kausar, Sulong Sarina, Husin Azlan & Ravindran Ankathil. (2022) Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. Frontiers in Oncology 12.
Crossref
Crossref
Jayastu Senapati & Koji Sasaki. (2022) Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers 14:10, pages 2533.
Crossref
Crossref
Veronica Balatti & Carlo M. Croce. (2022) Small Non-Coding RNAs in Leukemia. Cancers 14:3, pages 509.
Crossref
Crossref
Domenico Russo, José Valentín Garcia-Gutierrez, Simona Soverini & Michele Baccarani. (2020) Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. Journal of Clinical Medicine 9:6, pages 1709.
Crossref
Crossref
Snjezana Janjetovic, Anne Marie Asemissen, Frank Dicker, Mascha Binder, Judith Dierlamm, Carsten Bokemeyer & Philippe Schafhausen. (2019) Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. Tumori Journal 105:6, pages NP8-NP11.
Crossref
Crossref
Michael Lauseker, Katharina Bachl, Anna Turkina, Edgar Faber, Witold Prejzner, Ulla Olsson‐Strömberg, Michele Baccarani, Elza Lomaia, Daniela Zackova, Gert Ossenkoppele, Laimonas Griskevicius, Gabriele Schubert‐Fritschle, Tomasz Sacha, Sonja Heibl, Perttu Koskenvesa, Andrija Bogdanovic, Richard E. Clark, Joelle Guilhot, Verena S. Hoffmann, Joerg Hasford, Andreas Hochhaus & Markus Pfirrmann. (2019) Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American Journal of Hematology 94:11, pages 1236-1243.
Crossref
Crossref
Taisen Hao, Min Li-Talley, Alison Buck & WenYong Chen. (2019) An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific Reports 9:1.
Crossref
Crossref
Chung H. Kok, David T. Yeung, Liu LuDale B. WatkinsTamara M. LeclercqPhuong DangVerity A. SaundersJohn Reynolds, Deborah L. White & Timothy P. Hughes. (2019) Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances 3:10, pages 1610-1621.
Crossref
Crossref
Ramachandran Krishna Chandran, Narayanan Geetha, Kunnathur Murugesan Sakthivel, Chandran Geetha Aswathy, Preethi Gopinath, Thampirajan Vimaladevi Akhila Raj, Geetha Priya, Jagathnath Krishna Kumarapillai Mohanan Nair & Hariharan Sreedharan. (2019) Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. Gene 686, pages 85-91.
Crossref
Crossref
Camilla de S. Borges, Aline F. Ferreira, Vitor H. Almeida, Fausto G. Gomes, Maria Gabriela Berzoti-Coelho, Maira da Costa Cacemiro, Natalia S. Nunes, Lorena L. Figueiredo-Pontes, Belinda P. Simões, Fabíola A. Castro & Robson Q. Monteiro. (2018) Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental Hematology 66, pages 50-62.
Crossref
Crossref
Chetasi Talati & Javier Pinilla-Ibarz. (2018) Resistance in chronic myeloid leukemia. Current Opinion in Hematology 25:2, pages 154-161.
Crossref
Crossref
Preetesh Jain, Hagop M. Kantarjian, Ahmad Ghorab, Koji Sasaki, Elias J. Jabbour, Graciela Nogueras Gonzalez, Rashmi Kanagal-Shamanna, Ghayas C. Issa, Guillermo Garcia-Manero, Devendra KC, Sara Dellasala, Sherry Pierce, Marina Konopleva, William G. Wierda, Srdan Verstovsek, Naval G. Daver, Tapan M. Kadia, Gautam Borthakur, Susan O'Brien, Zeev Estrov, Farhad Ravandi & Jorge E. Cortes. (2017) Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123:22, pages 4391-4402.
Crossref
Crossref
Daniel Koch, Robert S. Eisinger & Alexander Gebharter. (2017) A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia. Journal of Theoretical Biology 433, pages 94-105.
Crossref
Crossref
Z Chen, C Shao, W Wang, Z Zuo, X Mou, S J Hu, J A DiGiuseppe, Y Zu, L J Medeiros & S Hu. (2016) Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 31:3, pages 585-592.
Crossref
Crossref
L.R. Tilova, A.V. Savinkova, E.M. Zhidkova, O.I. Borisova, T.I. Fetisov, K.A. Kuzin, O.A. Vlasova, A.S. Antipova, O.Yu. Baranova, K.I. Kirsanov, G.A. Belitskii, M.G. Yakubovskaya & Ekaterina Andreevna Lesovaya. (2017) Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems. Clinical oncohematology 10:2, pages 235-249.
Crossref
Crossref
Cristina Bucelli, Daniele Cattaneo, Valeria Ferla, Manuela Zappa, Caterina de Benedittis, Simona Soverini & Alessandra Iurlo. (2017) Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. Case Reports in Hematology 2017, pages 1-5.
Crossref
Crossref
Z Chen, J E Cortes, J L Jorgensen, W Wang, C C Yin, M J You, E Jabbour, H M Kantarjian, L J Medeiros & S Hu. (2016) Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia 30:7, pages 1606-1609.
Crossref
Crossref
Markéta Žáčková, Tereza Macháčková-Lopotová, Zuzana Ondráčková, Kateřina Kuželová, Hana Klamová & Jana Moravcová. (2016) Simplifying procedure for prediction of resistance risk in CML patients — Test of sensitivity to TKI ex vivo. Blood Cells, Molecules, and Diseases 58, pages 67-75.
Crossref
Crossref
Yukitsugu Nakamura, Katsuya Tokita, Fusako Nagasawa, Wataru Takahashi, Yuko Nakamura, Ko Sasaki, Motoshi Ichikawa & Kinuko Mitani. (2015) Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis. International Journal of Hematology 103:3, pages 348-353.
Crossref
Crossref
Elihu Estey. (2015) Why Is Progress in Acute Myeloid Leukemia So Slow?. Seminars in Hematology 52:3, pages 243-248.
Crossref
Crossref
Zachariah DeFilipp & Hanna Jean Khoury. (2015) Management of Advanced-Phase Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 10:2, pages 173-181.
Crossref
Crossref
Elihu EsteyRoss L. Levine & Bob Löwenberg. (2015) Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia. Blood 125:16, pages 2461-2466.
Crossref
Crossref
S. Sau?ele & Richard T. Silver. (2015) Management of chronic myeloid leukemia in blast crisis. Annals of Hematology 94:S2, pages 159-165.
Crossref
Crossref